CNS Pharmaceuticals Management
Management criteria checks 4/4
CNS Pharmaceuticals' CEO is John Climaco, appointed in Sep 2017, has a tenure of 6.67 years. total yearly compensation is $525.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 5.41% of the company’s shares, worth $127.25K. The average tenure of the management team and the board of directors is 4.9 years and 3.6 years respectively.
Key information
John Climaco
Chief executive officer
US$525.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 6.7yrs |
| CEO ownership | 5.4% |
| Management average tenure | 4.9yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CNS Pharmaceuticals reports Q2 results
Aug 15Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation
Dec 04
CNS Pharmaceuticals sinks after pricing equity offering of $10M
Dec 23How Many CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Shares Did Insiders Buy, In The Last Year?
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$525k | US$525k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$19m |
| Jun 30 2023 | n/a | n/a | -US$18m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$828k | US$525k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$13m |
| Jun 30 2022 | n/a | n/a | -US$14m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$846k | US$525k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$14m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$2m | US$440k | -US$9m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | US$1m | US$214k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$164k | US$150k | -US$7m |
| Dec 31 2017 | US$140k | US$50k | -US$526k |
Compensation vs Market: John's total compensation ($USD525.00K) is about average for companies of similar size in the US market ($USD667.96K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Climaco (54 yo)
6.7yrs
Tenure
US$525,000
Compensation
Mr. John Michael Climaco, Esq., J.D served as Chairman of the Board at CNS Pharmaceuticals, Inc. and joined CNS in September 2017. Mr. Climaco has been the Chief Executive Officer of CNS Pharmaceuticals, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.7yrs | US$525.00k | 5.41% $ 127.2k | |
| Chief Financial Officer | 4.5yrs | US$401.52k | 2.37% $ 55.6k | |
| Chief Medical Officer | no data | US$270.15k | 0.080% $ 1.9k | |
| Founder | no data | no data | no data | |
| Chief Science Officer | 4.9yrs | no data | no data |
4.9yrs
Average Tenure
61yo
Average Age
Experienced Management: CNSP's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | no data | US$525.00k | 5.41% $ 127.2k | |
| Independent Chairman of Board | 1.4yrs | US$112.64k | 0.013% $ 301.0 | |
| Independent Director | 5.9yrs | US$135.46k | 0.059% $ 1.4k | |
| Independent Director | less than a year | US$58.31k | 0.020% $ 461.1 | |
| Independent Director | 6.5yrs | US$115.16k | 1.09% $ 25.6k | |
| Independent Director | 5.8yrs | US$114.96k | 0.31% $ 7.4k | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | less than a year | no data | 0.0065% $ 152.6 |
3.6yrs
Average Tenure
56yo
Average Age
Experienced Board: CNSP's board of directors are considered experienced (3.6 years average tenure).